Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention

Overview

Journal Nanomaterials (Basel)

Date 2023 Mar 11

PMID 36903807

Authors

Md Abdullah Shamim

Ayaz Shahid

Pabitra K Sardar

Steven Yeung

Jeremiah Reyes

Jenny Kim

Cyrus Parsa

Robert Orlando

Jeffrey Wang

Kristen M Kelly

Frank L Meyskens Jr

Bradley T Andresen

Ying Huang

Affiliations

Soon will be listed here.

Abstract

The R-carvedilol enantiomer, present in the racemic mixture of the chiral drug carvedilol, does not bind to the β-adrenergic receptors, but exhibits skin cancer preventive activity. For skin delivery, R-carvedilol-loaded transfersomes were prepared using various ratios of drug, lipids, and surfactants, and characterized for particle size, zeta potential, encapsulation efficiency, stability, and morphology. Transfersomes were compared for in vitro drug release and ex vivo skin penetration and retention. Skin irritation was evaluated by viability assay on murine epidermal cells and reconstructed human skin culture. Single-dose and repeated-dose dermal toxicity was determined in SKH-1 hairless mice. Efficacy was evaluated in SKH-1 mice exposed to single or multiple ultraviolet (UV) radiations. Transfersomes released the drug at a slower rate, but significantly increased skin drug permeation and retention compared with the free drug. The transfersome with a drug-lipid-surfactant ratio of 1:3:0.5 (T-RCAR-3) demonstrated the highest skin drug retention and was selected for further studies. T-RCAR-3 at 100 µM did not induce skin irritation in vitro and in vivo. Topical treatment with T-RCAR-3 at 10 µM effectively attenuated acute UV-induced skin inflammation and chronic UV-induced skin carcinogenesis. This study demonstrates feasibility of using R-carvedilol transfersome for preventing UV-induced skin inflammation and cancer.

Citing Articles

Unravelling the success of transferosomes against skin cancer: Journey so far and road ahead.

Kumbhar P, Kamble V, Vishwas S, Kumbhar P, Kolekar K, Gupta G Drug Deliv Transl Res. 2024; 14(9):2325-2344.

PMID: 38758498 DOI: 10.1007/s13346-024-01607-9.

Lipid-based nanoparticles as a promising treatment for the skin cancer.

Golestani P Heliyon. 2024; 10(9):e29898.

PMID: 38698969 PMC: 11064151. DOI: 10.1016/j.heliyon.2024.e29898.

Transfersomes: Recent Advances, Mechanisms, Exhaustive Applications, Clinical Trials, and Patents.

Manchanda D, Makhija M, Pandey P, Sharma M Curr Drug Deliv. 2024; 22(2):215-230.

PMID: 38385485 DOI: 10.2174/0115672018295038240209055444.

Overcoming Skin Barrier with Transfersomes: Opportunities, Challenges, and Applications.

Dixena B, Madhariya R, Panday A, Ram A, Jain A Curr Drug Deliv. 2024; 22(2):160-180.

PMID: 38178667 DOI: 10.2174/0115672018272012231213100535.

Nitric oxide synergizes minoxidil delivered by transdermal hyaluronic acid liposomes for multimodal androgenetic-alopecia therapy.

Xing H, Peng H, Yang Y, Lv K, Zhou S, Pan X Bioact Mater. 2023; 32:190-205.

PMID: 37859688 PMC: 10582348. DOI: 10.1016/j.bioactmat.2023.09.021.

References

Zhai H, Leow Y, Maibach H . Human barrier recovery after acute acetone perturbation: an irritant dermatitis model. Clin Exp Dermatol. 1998; 23(1):11-3. DOI: 10.1046/j.1365-2230.1998.00310.x. View

Nichols A, Sulpizio A, Ashton D, Hieble J, Ruffolo Jr R . The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989; 1(4):265-70. DOI: 10.1002/chir.530010404. View

Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H . Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim). 1993; 326(9):529-33. DOI: 10.1002/ardp.19933260907. View

Cevc G, Blume G . New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta. 2001; 1514(2):191-205. DOI: 10.1016/s0005-2736(01)00369-8. View

von Mollendorff E, REIFF K, Neugebauer G . Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987; 33(5):511-3. DOI: 10.1007/BF00544245. View

Bartsch W, Sponer G, Strein K, Kling L, Bohm E, Martin U . Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol. 1990; 38 Suppl 2:S104-7. DOI: 10.1007/BF01409475. View

Kandarova H, Hayden P, Klausner M, Kubilus J, Kearney P, Sheasgreen J . In vitro skin irritation testing: Improving the sensitivity of the EpiDerm skin irritation test protocol. Altern Lab Anim. 2010; 37(6):671-89. DOI: 10.1177/026119290903700611. View

Liang S, Shamim M, Shahid A, Chen M, Cleveland K, Parsa C . Prevention of Skin Carcinogenesis by the Non-β-blocking R-carvedilol Enantiomer. Cancer Prev Res (Phila). 2021; 14(5):527-540. PMC: 8102373. DOI: 10.1158/1940-6207.CAPR-20-0609. View

Fujimaki M . Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality. 1992; 4(3):148-54. DOI: 10.1002/chir.530040304. View

10.

Chang A, Yeung S, Thakkar A, Huang K, Liu M, Kanassatega R . Prevention of skin carcinogenesis by the β-blocker carvedilol. Cancer Prev Res (Phila). 2014; 8(1):27-36. PMC: 4289657. DOI: 10.1158/1940-6207.CAPR-14-0193. View

11.

Huang K, Liang S, Yeung S, Oiyemhonlan E, Cleveland K, Parsa C . Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prev Res (Phila). 2017; 10(10):598-606. DOI: 10.1158/1940-6207.CAPR-17-0132. View

12.

Mahmood S, Taher M, Mandal U . Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. Int J Nanomedicine. 2014; 9:4331-46. PMC: 4168883. DOI: 10.2147/IJN.S65408. View

13.

Elsayed M, Abdallah O, Naggar V, Khalafallah N . Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie. 2007; 62(2):133-7. View

14.

Roberts M, Cheruvu H, Mangion S, Alinaghi A, Benson H, Mohammed Y . Topical drug delivery: History, percutaneous absorption, and product development. Adv Drug Deliv Rev. 2021; 177:113929. DOI: 10.1016/j.addr.2021.113929. View

15.

Elsayed M, Abdallah O, Naggar V, Khalafallah N . Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm. 2007; 332(1-2):1-16. DOI: 10.1016/j.ijpharm.2006.12.005. View

16.

Benson H, Grice J, Mohammed Y, Namjoshi S, Roberts M . Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies. Curr Drug Deliv. 2019; 16(5):444-460. PMC: 6637104. DOI: 10.2174/1567201816666190201143457. View

17.

Dick I, Scott R . Pig ear skin as an in-vitro model for human skin permeability. J Pharm Pharmacol. 1992; 44(8):640-5. DOI: 10.1111/j.2042-7158.1992.tb05485.x. View

18.

Shamim M, Yeung S, Shahid A, Chen M, Wang J, Desai P . Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption. Int J Pharm. 2021; 611:121302. PMC: 8692451. DOI: 10.1016/j.ijpharm.2021.121302. View

19.

Faller C, Bracher M, Dami N, Roguet R . Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics. Toxicol In Vitro. 2002; 16(5):557-72. DOI: 10.1016/s0887-2333(02)00053-x. View

20.

El Zaafarany G, Awad G, Holayel S, Mortada N . Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm. 2010; 397(1-2):164-72. DOI: 10.1016/j.ijpharm.2010.06.034. View